Clinical
Lilly’s Oral Obesity Pill Falls Short of Wegovy Expectations
Eli Lilly’s highly anticipated oral obesity treatment orforglipron delivered solid but underwhelming results in its Phase 3 trial, triggering a dramatic market reaction that wiped
Key clinical trial readouts, study launches, safety data, design changes, and patient outcomes across Phase 1–3 programs in biotech, medtech, and pharma.
Eli Lilly’s highly anticipated oral obesity treatment orforglipron delivered solid but underwhelming results in its Phase 3 trial, triggering a dramatic market reaction that wiped
Strategic Pipeline Focus as Competitive Pressures Mount Against Lilly Novo Nordisk’s recent decision to drop two obesity drug candidates—another GLP-1/GIP co-agonist and CB1 receptor as
Key Takeaways: FDA approvals in 2025 have highlighted therapies addressing rare diseases, oncology, and chronic conditions. Innovative drugs with new mechanisms of action are transforming
Quick Summary •Setback: Neurogene reported an adverse event in its high-dose gene therapy trial for Rett syndrome, involving liver toxicity and immune responses. •Key Issue:
Quick Summary Event: Neurogene’s stock fell 44% after reporting a severe adverse event in its high-dose gene therapy trial for Rett syndrome. Clinical Concern: The
Quick Summary Clinical Data: Viking Therapeutics reported positive weight-loss results from trials of its oral obesity drug candidate. Market Reaction: Despite the positive clinical data,
Quick Summary Therapy: Apitegromab, a muscle-targeted monoclonal antibody Trial Outcome: Significant improvements in motor function for non-ambulatory SMA patients Regulatory Plans: Scholar Rock intends to
Quick Summary Trial Result: Eli Lilly’s Taltz (ixekizumab) outperformed Janssen’s Tremfya (guselkumab) in a head-to-head Phase IV study. Primary Outcome: 41% of patients treated with
Quick Summary Key Result: Intellia Therapeutics reports up to an 81% reduction in angioedema attacks for high-dose recipients in its Phase 2 trial. Therapeutic Potential:
Quick Summary Trial Outcome: Boston Scientific’s Acurate neo2 transcatheter aortic valve replacement (TAVR) system missed its primary endpoint in a critical trial. Comparison Results: Acurate